Spirogen is a clinical stage biotechnology company specialising in novel, sequence-selective, DNA minor groove-binding molecules with potent therapeutic properties. Spirogen's principal technology revolves around the modification of members of a group of natural antibiotics called pyrrolobenzodiazepines (PBDs).. The company was founded in 2000, has 10 employees and is venture capital funded.
Spirogen's lead oncology drug candidate, SG2000, has completed solid tumor Phase I studies in the USA and Europe. A hematological Phase I study is ongoing in the USA. A Phase II studiy in ovarian cancer is planned for first dosing in Q4 2009.
Currently, Spirogen's pipeline comprises two well characterised, DNA minor groove-binding, interstrand cross-linking, PBD dimer molecules, SG2000 and SG2285, plus a number of earlier stage leads. Additionally the achiral duocarmycin analogue, AS-1-145 (Centanamycin), is now in pre-clinical development with the NCI and the NF-Y transcription factor-targeted agent SG2274 is in late discovery.
A number of Spirogen's highly potent antineoplastic molecules are under evaluation with pharmaceutical companies as candidates for development as warheads in antibody drug conjugate therapies. Spirogen has an active program of ADC warhead and linker development.
Please visit our History page for a brief summary of some of the key corporate milestones in Spirogen's history.
